Method To Prevent Biofilm Formation in Various Clinical Settings (Contact Lenses, Wounds, Cystic Fibrosis, etc.)

Tech ID: 04-08


Video - New Method Attacks Bacterial Infections of Contact Lenses



Researchers at National Jewish Health have determined that actin originating from necrotized human neutrophils serve as a biological matrix in the formation of microbial biofilms in the airways of cystic fibrosis (CF) patients.  Since biofilm formation allows for the survival of microbial organisms in the airways of CF patients and is also associated with increased morbidity and mortality, targeting actin and/or neutrophils could be the basis for the development of a potential therapy for CF.


Targeted therapy for preventing or reducing biofilm formation in cystic fibrosis, infectious kidney stones, cystitis, dental caries, chronic otitis media, bacterial endocarditis, osteomyelitis, wounds, and acne.

Prevention of microbial biofilm development on contact lenses, orthopedic implants, stents, catheters and other medical devices.

An assay to test compounds for their ability to prevent/reduce biofilm formation by assessing the ability of microbial organizations to bind actin.

Advantages of Invention

This therapy, focused on biofilm prevention or degradation, is particularly applicable for early stage CF in young patients when antimicrobial agents are only partially effective at best.

State of Development

Our scientists have shown the following in vitro:

  • Biofilm development of P. aeruginosa is enhanced with:

    • the addition of human viable neutrophils and correlates with an increase in the number of necrotic neutrophils.

    • the addition of neutrophils lysates and particularly with monomeric actin (G-actin).

  • Biofilm development of P. aeruginosa is reduced with:

    • the addition of neutrophils lysates depleted of actin microfilaments (F-actin).

    • the addition of compunds that promotes the depolymerization of F-actin, such as gelsolin or charged poly(amino acids).


Further R&D Required

Using the state grant to identify the most effective charged poly(amino acids) at disrupting biofilms and testing such compounds on infected contact lenses, and in animal models of eye and skin infections.



  • Walker, T. S., K. L. Tomlin, G. S. Worthen, K. R. Poch, J. G. Lieber, M. T. Saavedra, M. B. Fessler, K. C. Malcolm, M. L. Vasil, and J. A. Nick. "Enhanced Pseudomonas Aeruginosa Biofilm Development Mediated by Human Neutrophils." Infection and Immunity 73.6 (2005): 3693-701. Print. PMID:  15908399

  • Parks, Q. M., R. L. Young, K. R. Poch, K. C. Malcolm, M. L. Vasil, and J. A. Nick. "Neutrophil Enhancement of Pseudomonas Aeruginosa Biofilm Development: Human F-actin and DNA as Targets for Therapy." Journal of Medical Microbiology 58.4 (2009): 492-502. Print. PMCID: PMC2677169.

  • Robertson, D. M., Q. M. Parks, R. L. Young, J. Kret, K. R. Poch, K. C. Malcolm, D. P. Nichols, M. Nichols, M. Zhu, H. D. Cavanagh, and J. A. Nick. "Disruption of Contact Lens-Associated Pseudomonas Aeruginosa Biofilms Formed in the Presence of Neutrophils." Investigative Ophthalmology & Visual Science 52.5 (2011): 2844-850. Print. PMID: 21245396.



J.A. Nick, MD, T.S. Walker, G.S. Worthen, MD, Quinn Parks, PhD



U.S. Patents #8,753,662 and #8,901,167. Additional patents pending.
Published U.S. Patent Application #20060030539; Published U.S. Patent Application #20080207556; Published U.S. Patent Application #20080199509; International Patent Application #WO2006/017816. An additional patent application pending.


Licensing Status

This technology is available for licensing.


For Further Information, Contact:

Emmanuel Hilaire, PhD
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: 303.398.1262
Fax: 303.270.2352

Bookmark and Share

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our Faculty by Area of Research.